Q4 2025 · 13F-HR
Nan Fung Group Holdings Ltdholdings as filed
Filed 2026-02-13 · accession 0001012975-26-000144
$111.7M
Reported value
27
Positions
2025-12-31
Period end
The Brief · Nan Fung Group Holdings Ltd · Q4 2025
AI · grounded in 13F
Nan Fung Group Holdings Ltd initiated a new position in EVMN valued at $24.67M. The fund also added new stakes in MPLT for $17.06M, PCOR for $3.88M, and HELP for $3.76M. Offsets included closing its entire position in JOBY for a reduction of $3.51M and trimming its holding in RKLB by 87.05%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 30054Y107 | EVMN | EVOMMUNE INC | $24.7M | 22.1% | 1,441,032 | Common | SOLE |
| 56565P103 | MPLT | MAPLIGHT THERAPEUTICS INC | $17.1M | 15.3% | 971,253 | Common | SOLE |
| H5870P102 | OCS | OCULIS HOLDING AG | $10.3M | 9.20% | 514,702 | Common | SOLE |
| 558868105 | MDGL | MADRIGAL PHARMACEUTICALS INC | $6.9M | 6.19% | 11,872 | Common | SOLE |
| 50180M108 | LBRX | LB PHARMACEUTICALS INC | $6.7M | 5.98% | 300,000 | Common | SOLE |
| 45337C102 | INCY | INCYTE CORP | $5.8M | 5.22% | 59,022 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $5.3M | 4.71% | 49,120 | Common | SOLE |
| 07725L102 | ONC | BEONE MEDICINES LTD | $4.8M | 4.28% | 15,722 | Common | SOLE |
| 74275K108 | PCOR | PROCORE TECHNOLOGIES INC | $3.9M | 3.47% | 53,299 | Common | SOLE |
| 23256X407 | HELP | CYBIN INC | $3.8M | 3.37% | 460,000 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S | $2.9M | 2.60% | 13,600 | Common | SOLE |
| 004225108 | ACAD | ACADIA PHARMACEUTICALS INC | $2.8M | 2.46% | 102,984 | Common | SOLE |
| 75629V104 | RXRX | RECURSION PHARMACEUTICALS IN | $2.4M | 2.18% | 595,287 | Common | SOLE |
| 34385P108 | LAB | STANDARD BIOTOOLS INC | $2.4M | 2.16% | 1,883,179 | Common | SOLE |
| 501575104 | KYMR | KYMERA THERAPEUTICS INC | $2.4M | 2.15% | 30,875 | Common | SOLE |
| 04016X101 | ARGX | ARGENX SE | $2.4M | 2.11% | 2,800 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $1.5M | 1.37% | 19,253 | Common | SOLE |
| 46438R105 | ETHA | ISHARES ETHEREUM TR | $1.1M | 1.01% | 50,549 | Common | SOLE |
| 413197104 | HRMY | HARMONY BIOSCIENCES HLDGS IN | $1.0M | 0.91% | 27,049 | Common | SOLE |
| 46438F101 | IBIT | ISHARES BITCOIN TRUST ETF | $792,811 | 0.71% | 15,968 | Common | SOLE |
| 753018100 | RANI | RANI THERAPEUTICS HLDGS INC | $666,338 | 0.60% | 493,584 | Common | SOLE |
| 76029N106 | REPL | REPLIMUNE GROUP INC | $619,349 | 0.55% | 63,719 | Common | SOLE |
| 29384C108 | TRDA | ENTRADA THERAPEUTICS INC | $504,563 | 0.45% | 49,082 | Common | SOLE |
| 088786108 | BCYC | BICYCLE THERAPEUTICS PLC | $488,116 | 0.44% | 68,943 | Common | SOLE |
| 097702203 | BOLT | BOLT BIOTHERAPEUTICS INC | $319,041 | 0.29% | 58,347 | Common | SOLE |
| 773121108 | RKLB | ROCKET LAB CORP | $266,762 | 0.24% | 3,824 | Common | SOLE |
| 09769B206 | BSLK | BOLT PROJS HLDGS INC | $32,437 | 0.03% | 40,597 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.